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General Information.  Commercial reagents were purified prior to use following the
guidelines of Perrin and Armarego.1  Organic solutions were concentrated under reduced
pressure on a Buchi rotary evaporator.  Chromatographic purification of products was
accomplished using forced-flow chromatography on ICN 60 32-64 mesh silica gel 63 according
to the method described by Still.2 Thin-layer chromatography (TLC) was performed on EM
Reagents 0.25 mm silica gel 60-F plates.  Visualization of the developed chromatogram was
performed by florescence quenching or KMnO4 stain.
1H NMR and 13C NMR spectra were recorded on Bruker AM-400 (400 MHz and 100
MHz, respectively), Bruker DRX-500 (500 MHz and 125 MHz, respectively), Varian Mercury-
300 (300 MHz and 75 MHz, respectively), or Varian I-500 (500 MHz and 125 MHz,
respectively) instruments, as noted, and are internally refernced to residual protio solvent signals.
Data for 1H NMR are reported with chemical shift (d ppm), multiplicity (s = singlet, d = doublet,
t = triplet, q = quartet, m = multiplet), integration, coupling constant (Hz), and assignment.  Data
for 13C NMR are reported with chemical shift.  IR spectra were recorded on an ASI React-IR
1000 spectrometer and are reported in terms of frequency of absorption (cm-1).  Optical Rotations
were recorded on a Jasco P-1010 polarimeter (WI lamp, 589 nm, 25°C).  Mass spectra were
obtained from the UC Irvine Mass Spectral Facility.  Gas Chromatography was performed on
Hewlett-Packard 5890A and 6890 Series gas chromatographs equipped with a split-mode
capillary injection system and flame ionization detectors using a Bodman Chiraldex G-TA (30 m
x 0.25 mm) column.  HPLC analysis was performed on a Hewlett-Packard 1100 Series HPLC at
                                                
1 Perrin, D. D.; Armarego, W.L.F. Purification of Laboratory Chemicals; 3rd ed., Pregamon Press, Oxford, 1988.
2 Still, W.C.; Kahn, M.; Mitra, A. J. J. Org. Chem. 1978, 43, 2923.
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254nm using the following Chiralcel columns: OD-H (25 cm) and OD guard (5 cm), AD (25 cm)
and AD guard (5 cm).
(5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one trifluoromethanesulfonic acid salt
(5).  Prepared from the hydrochloride salt 1a3 by reatment with saturated aq. NaHCO3 (100 mL)
and extraction of the free amine with CHCl3 (3 x 100 mL).  The solution was dried over Na2SO4,
filtered, and concentrated.  The residue was taken up in Et2O and trifluoromethanesulfonic acid
was added to precipitate 5.  The precipitate was recrystallized from 2-propanol to provide the
title compound as colorless crystals.  IR (CH2Cl2) 2363, 1730, 1290, 1182 cm
-1; 1H NMR (300
MHz, d6-DMSO) d  10.35 (br s, 1H, 
+NH2), 9.27 (br s, 1H, 
+NH2), 7.19–7.38 (m, 5H, C6H5), 4.67
(br d, J = 8.6 Hz, 1H, COCH), 3.30 (dd, J  = 3.3, 15.4 Hz, 1H, C2 6H5), 2.93 (dd, J  = 11.0, 15.4
Hz, 1H, CH2C6H5), 2.79 (s, 3H, CH3NCO), 1.62 (s, 3H, CH3), 1.48 (s, 3H, CH3); 
13C NMR (75
MHz, CDCl3) d  166.8, 136.6, 129.7, 129.3, 127.8, 77.5, 57.9, 34.4, 25.7, 24.6, 22.5; LRMS (CI)
m/z 219 (MH)+; HRMS (CI) exact mass calcd for (C17H19N2O)
+ requires m/z 219.1497, found m/z
219.1497;  [a ]D = –58.8 (c = 1.0, CH3O ).
(5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one trifluoroacetic acid salt (6).
Prepared from the hydrochloride salt 1a by reatment with saturated aq. NaHCO3 (100 mL) and
extraction of the free amine with CHCl3 (3 x 100 mL).  The solution was dried over Na2SO4,
filtered, and concentrated.  The residue was taken up in Et2O and trifluoroacetic acid was added
to precipitate the title compound as white crystals.  IR (film) 3437, 2920, 2742, 2518, 2418,
1722, 1653, 1491, 1429, 1398, 1274, 1182, 1074, 834, 695 cm-1; 1H NMR (300 MHz, d6-DMSO)
d  9.97 (br s, 1H, +NH2), 7.22–7.37 (m, 5H, C6H5), 4.53 (br d, J = 7.1 Hz, 1H, COCH), 3.27 (dd, J
= 3.3, 14.8 Hz, 1H, CH2 6H5), 3.00 (dd, J  = 10.2, 14.8 Hz, 1H, C2C6H5), 2.76 (s, 3H,
CH3NCO), 1.59 (s, 3H, CH3), 1.46 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3) d  167.6, 136.9,
129.8, 129.1, 127.5, 77.2, 58.0, 34.7, 25.6, 24.7, 22.8; LRMS (EI) m/z 218 (M+; HRMS (EI)
exact mass calcd for (C17H19N2O)
+ requires m/z 219.1497, found m/z219.1494;  [a ]D = –63.2 (c =
1.0, CHCl3).
                                                
3 Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243.
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(5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one hydrobromide (7).  Prepared from
the hydrochloride salt 1  by treatment with saturated aq. NaHCO3 (100 mL) and extraction of the
free amine with CHCl3 (3 x 100 mL).  The solution was dried over Na2SO4, filtered, and
concentrated.  The residue was taken up in Et2O and hydrobromic acid was added to precipitate
the title compound as white crystals.  IR (film) 3414, 2912, 2711, 2557, 1707, 1607, 1390, 1274,
1197, 1159, 1058, 989, 703 cm-1; 1H NMR (300 MHz, d6-DMSO) d  10.41 (brs, 1H, 
+NH2), 9.69
(br s, 1H, +NH2), 7.24–7.43 (m, 5H, C6H5), 4.69 (br d, J = 7.1 Hz, 1H, COCH), 3.28 (dd, J  = 3.0,
15.1 Hz, 1H, CH2C6H5), 3.15 (dd, J  = 10.4, 14.8 Hz, 1H, C2C6H5), 2.77 (s, 3H, CH3NCO), 1.67
(s, 3H, CH3), 1.49 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3) d  166.8, 136.7, 129.9, 129.2, 127.7,
77.6, 58.1, 33.9, 25.8, 24.5, 22.6; LRMS (EI) m/z218 (M)+; HRMS (EI) exact mass calcd for
(C17H18N2O)
+ requires m/z 218.1419, found m/z 218.1420;  [a ]D = –21.3 (c = 1.0, CHCl3).
(5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt (8).  Prepared
from the hydrochloride salt 1a by treatment with saturated aq. NaHCO3 (100 mL) and extraction
of the free amine with CHCl3 (3 x 100 mL).  The solution was dried over Na2SO4, filtered, and
concentrated.  The residue was taken up in Et2O and perchloric acid was added to precipitate the
title compound as white crystals.  IR (film) 3514, 3059, 2927, 2850, 1707, 1607, 1398, 1267,
1097, 927. 703 cm-1; 1H NMR (300 MHz, d6-DMSO) d  10.37 (br s, 1H, 
+NH2), 9.25 (br s, 1H,
+NH2), 7.26–7.43 (m, 5H, C6H5), 4.66 (br d, J = 8.8 Hz, 1H, COCH), 3.33 (dd, J  = 3.3, 15.1 Hz,
1H, CH2C6H5), 2.94 (dd, J  = 10.7, 15.1 Hz, 1H, C2C6H5), 2.78 (s, 3H, CH3NCO), 1.62 (s, 3H,
CH3), 1.48 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3) d  166.8, 136.5, 129.7, 129.3, 127.8, 77.6,
58.0, 34.4, 25.7, 24.6, 22.5; LRMS (EI) m/z 218 (M)+; HRMS (CI) exact mass calcd for
(C17H18NO2)
+ requires m/z 218.1419, found m/z 218.1428;  [a ]D = –61.1 (c = 1.0, CH3NO2).
General Procedure A.  A flask containing nitrone and imidizolidinone catalyst was
charged with CH3NO2, then treated with the appropriate amount of H2O.  After cooling the
solution to the desired temperature, a ,b  nsaturated aldehyde was added dropwise to the flask.
After the appropriate reaction time, the resulting solution was passed through a silica gel column
with ethyl acetate.  Removal of volatiles resulted in an oily residue, which was purified by silica
gel chromatography to afford the title compounds.
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General Procedure B.  A flask containing nitrone and imidizolidinone catalyst was
charged with CH3NO2, then treated with the appropriate amount of H2O.  After cooling the
solution to the desired temperature, a ,b  nsaturated aldehyde was added dropwise to the flask.
Additional aldehyde was added to the reaction mixture at 24 h intervals until the specified
reaction time was reached.  The resulting solution was passed through a silica gel column with
ethyl acetate.  Removal of volatiles resulted in an oily residue, which was purified by silica gel
chromatography to afford the title compounds.
General Procedure C: The Reduction of Isoxazolidine Products.  To a olution of the
isoxazolidine aldehyde in absolute ethanol (1ml) were added 3 equivalents of NaBH4.  After 0.5
hours, the reaction mixture was quenched with H2O, and extracted with 2 x 10mL of CH2Cl2.
The organic layer was dried over Na2SO4, filtered, and concentrated.  Purification of the resultant
residue by silica gel chromatography provided the corresponding primary alcohol.
(3R,4S,5R)-2-Benzyl-4-formyl-5-methyl-3-phenylisoxazolidine (Table 3, entry 1).
Prepared according to general procedure B from (Z)-N-benzylidenebenzylamine N-oxide (5.28 g,
25.0 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt (8) (1.59 g,
5.00 mmol), crotonaldehyde (8.28 mL, 100.0 mmol followed by 5 x 6.21 mL, 75.0 mmol over 24
h intervals ) and H2O (1.35 mL, 75.0 mmol) in CH3NO2 (250.0 ml) at  –20 ˚C over the course of
144 h.  The resulting solution was passed through a silica gel column with CH2Cl2 to provide the
title compound as an oil in 98% yield (6.85 g); 94:6 endo:exo.  Endo isomer: IR (CH2Cl2) 2853,
1722, 1494, 1455, 1374 cm-1; 1H NMR (400 MHz, CDCl3) d  9.81 (d, J = 2.4 Hz, 1H, CHO),
7.24–7.58 (m, 10H, C6H5 and CH2C6H5), 4.57 (dq, J  = 6.1, 12.2 Hz, 1H, CCH3), 4.21 (d, J  =
7.8 Hz, 1H, CHC6H5), 4.02 (d, J  = 14.4 Hz, 1H, CH2 6H5), 3.84 (d, J  = 14.3 Hz, 1H, CH2 6H5),
3.15 (m, 1H, CH HO), 1.52 (d, J  = 6.2 Hz, 3H, CH3); 
13C NMR (100 MHz, CDCl3) d  198.5,
138.4, 137.3, 129.0, 128.6, 128.3, 128.2, 127.5, 127.1, 73.4, 71.5, 71.1, 59.5, 21.2; LRMS (CI)
m/z 281 (M)+; HRMS (CI) exact mass calcd for (C18H19NO2) requires m/z 281.1418, found m/z
281.1413 (M)+; [a ]D = +82.5 ° (c = 1.0, CHCl3).  Diastereomeric ratios were determined by 
1H
NMR analysis.  A portion of the title compound was reduced to the corresponding primary
alcohol (general procedure C) and purified by silica gel chromatography (3:7 EtOAc/hexane) for
the determination of enantiomeric purity; endo 94% ee. 1H NMR (500 MHz, CDCl3) d  7.22–7.47
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(m, 10H, ArH), 4.22-4.24 (m, 1H, CON), 4.00 (d, J  = 14.6 Hz, 1H, CH2C6H5), 3.81 (d, J  = 14.6
Hz, 1H, CH2C6H5), 3.74-3.75 (m, 2H, C2OH), 3.65 (d, J  = 8.3 Hz, 1H, CH 6H5), 2.36-2.42 (m,
1H, CHCH2OH), 1.46 (d, J  = 6.4 Hz, 3H, CH3).  Enantiomeric ratios were determined by HPLC
with a Chiralcel OD-H column and OD guard column (1:39 iPrOH/hexane, 1 mL/min flow rate);
endo isomers tr = 59.3 min (major enantiomer) and 76.3 min (minor enantiomer).
(3R,4S,5R)-2-Allyl-4-formyl-5-methyl-3-phenylisoxazolidine (Table 3, entry 2).
Prepared according to general procedure B from (Z)-N-benzylideneallylamine N-oxide (63 mg,
0.30 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt (8) (19 mg,
0.08 mmol), crotonaldehyde (133 m L, 1.6 mmol followed by 5 x 75 m L, 1.2 mmol over 24 h
intervals) and H2O (22 m L, 1.2 mmol) in CH3NO2 (4.0 ml) at –20 ˚C over the course of 132 h to
provide the title compound as a colorless oil in 73% yield (68 mg); 93:7 endo:exo. Endo isomer:
IR (CH2Cl2) 2981, 2842, 1722, 1645, 1498, 1376 cm
-1; 1H NMR (300 MHz, CDCl3) d  9.77 (d, J
= 2.2 Hz, 1H, CHO), 7.14–7.24 (m, 5H, C6H5), 5.84–5.98 (m, 1H, CH2=CHCH2), 5.06–5.28 (m,
2H, CH2=CH), 4.51 (dq, J  = 6.0, 6.0 Hz, 1H, CHCH3), 4.10 (d, J  = 7.7 Hz, 1H, CH 6H5), 3.46
(dd, J  = 5.5, 14.3 Hz, 1H, CH2=CHCH2N), 3.31 (dd, J  = 6.6, 14.3 Hz, 1H, CH2=CHCH2N), 3.09
(ddd, J  = 2.5, 5.8, 8.0 Hz, 1H, CCHO), 1.50 (d, J  = 6.0 Hz, 3H, CH3); 
13C NMR (100 MHz,
CDCl3) d  198.7, 138.6, 133.9, 129.1, 128.4, 127.8, 118.1, 73.7, 71.9, 71.3, 59.1, 21.3; LRMS
(CI) m/z 231 (M)+; HRMS (CI) exact mass calcd for (C14H17NO2) requires m/z 231.1259, found
m/z 231.1256 (M)+; [a ]D = +63.8 ° (c = 1.0, CHCl3).  Diastereomeric ratios were determined by
1H NMR analysis.  A portion of the title compound was reduced to the corresponding primary
alcohol (general procedure C) and purified by silica gel chromatography (3:7 EtOAc/hexane) for
the determination of enantiomeric purity; endo 98% ee.  1H NMR (300 MHz, CDCl3) d
7.13–7.41 (m, 5H, C6H5), 5.83–5.97 (m, 1H, CH2=CHCH2), 5.08–5.22 (m, 2H, C2=CH), 4.21
(dq, J  = 6.4, 6.4 Hz, 1H, CHCH3), 3.64–3.83 (br s, 2H, C2OH), 3.57 (d, J  = 8.0 Hz, 1H,
CHC6H5), 3.44 (dd, J  = 5.2, 14.3 Hz, 1H, CH2=CHCH2N), 3.28 (dd, J  = 6.6, 14.3 Hz, 1H,
CH2=CHCH2N), 2.34 (m, 1H, CH H2OH), 1.44 (d, J  = 6.1 Hz, 3H, CH3).  Enantiomeric ratios
were determined by HPLC with a Chiralcel AD column and AD guard column (3:97
EtOH/hexane, 1 mL/min flow rate); endo isomers tr = 18.2 min and 24.2 min.
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(3R,4S,5R)-2,5-Dimethyl-4-formyl-3-phenylisoxazolidine (Table 3, entry 3). Prepared
according to general procedure B from (Z)-N-benzylidenemethylamine N-oxide (54.1 mg, 0.40
mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt (8) (26 mg, 0.08
mmol), crotonaldehyde (133 m L, 1.6 mmol followed by 5 x 100 m L, 1.2 mmol, over 24 h
intervals) and H2O (22 m L, 1.2 mmol) in CH3NO2 (4.0 ml) at  –20 ˚C over the course of 132 h to
provide the title compound as a colorless oil in 66% yield (54 mg); 95:5 endo:exo. Endo >99%
ee Endo isomer: IR (CH2Cl2) 2974, 2873, 1722, 1552 cm
-1; 1H NMR (300 MHz, CDCl3) d  9.74
(d, J  = 2.5 Hz, 1H, CHO), 7.26–7.39 (m, 5H, C6H5), 4.54 (dq, J  = 6.0, 12.3 Hz, 1H, CCH3),
3.83 (br s, 1H, CH 6H5), 3.09 (m, 1H, CH HO), 2.60 (s, 3H, NCH3), 1.50 (d, J  = 6.3 Hz, 3H,
CHCH3); 
13C NMR (75 MHz, CDCl3) d  198.6, 137.8, 129.1, 128.5, 127.8, 73.5, 72.2, 66.3, 43.6,
21.9; LRMS (CI) m/z 205 (M)+; HRMS (CI) exact mass calcd for (C12H15NO2) requires m/z
205.1103, found m/z205.1100 (M)+; [a ]D = +77.2 ° (c = 1.0, CHCl3).  Diastereomeric ratios were
determined by  1H NMR analysis.  Enantiomeric ratios were determined by GLC with a Bodman
b -PH column (100 °C, 23 psi); endo isomers tr = 38.0 min and 39.8 min.
(3R,4S,5R)-2-Benzyl-4-formyl-5-methyl-3-(4-chlorophenyl) isoxazolidine (Table 3,
entry 4).  Prepared according to general procedure B from (Z)-N-para-
chlorobenzylidenebenzylamine N-oxide (74 mg, 0.30 mmol), (5S)-5-Benzyl-2,2,3-
trimethylimidazolidin-4-one perchloric acid salt (8) (19 mg, 0.06 mmol), crotonaldehyde (100
m L, 1.2 mmol followed by 7 x 75 m L, 0.90 mmol, over 24 h intervals) and H2O (16 m L, 0.90
mmol) in CH3NO2 (3.0 ml) at  –20 ˚C over the course of 160 h.  The resulting solution was
passed through a silica gel column with CH2Cl2 to provide the title compound as an oil in 78%
yield (74 mg); 92:8 endo:exo.  Endo isomer: IR (film) 3429, 3066, 2981, 2873, 2835, 2726,
1722, 1599, 1491, 1452, 1375, 1089, 1020, 819, 734, 703 cm-1; 1H NMR (300 MHz, CDCl3) d
9.79 (d, J = 2.2 Hz, 1H, CHO), 7.24–7.38 (m, 9H, C6H4 l and CH2C6H5), 4.55 (m, 1H, CH H3),
4.16 (d, J = 7.7 Hz, 1H, CH 6H4Cl), 3.97 (d, J  = 14.0 Hz, 1H, CH2 6H5), 3.84 (d, J  = 14.3 Hz,
1H, CH2C6H5), 3.06 (ddd, J  = 7.4, 5.5, 2.2 Hz, 1H, CCHO), 1.50 (d, J  = 6.0 Hz, 3H, CH3); 
13C
NMR (125 MHz, CDCl3) d  198.6, 137.5, 137.2, 134.1, 129.8, 129.6, 129.4, 129.1, 128.8, 128.6,
127.6, 21.3; LRMS (CI) m/z 315 (M)+; HRMS (CI) exact mass calcd for (C18H18NClO2) requires
m/z 315.1026, found m/z315.1023 (M)+; [a ]D = +69.8 (c = 1.0, CHCl3).  Diastereomeric ratios
were determined by 1H NMR analysis.  A portion of the title compound was reduced to the
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corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 95% ee. 1H NMR (500
MHz, CDCl3) d  7.24–7.39 (m, 9H, ArH), 4.23 (m, 1H, CHON), 3.97 (d, J  = 14.2 Hz, 1H,
CH2C6H5), 3.84 (d, J  = 14.2 Hz, 1H, CH2 6H5), 3.73-3.81 (m, 2H, C2OH), 3.67 (d, J  = 7.8 Hz,
1H, CHC6H4Cl), 2.31-2.33 (m, 1H, CCH2OH), 1.44 (d, J  = 6.4 Hz, 3H, CH3).    Enantiomeric
ratios were determined by HPLC with a Chiralcel AD column and AD guard column (3:125
EtOH/hexane, 1 mL/min flow rate); endo isomers tr = 47.7 min and 83.6 min.
(3R,4S,5R)-2,5-Dimethyl-4-formyl-3-(4-chlorophenyl) isoxazolidine (Table 3, entry
5).  Prepared according to general procedure B from (Z)-N-para-chlorobenzylidenemethylamine
N-oxide (68 mg, 0.40 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid
salt (8) (26 mg, 0.08 mmol), crotonaldehyde (133 m L, 1.6 mmol followed by 8 x 100 m L, 1.20
mmol, over 24 h intervals) and H2O (22 m L, 1.20 mmol) in CH3NO2 (4.0 ml) at  –20 ˚C over the
course of 160 h.  The resulting solution was passed through a silica gel column with CH2Cl2 to
provide the title compound as an oil in 76% yield (73 mg); 93:7 endo:exo.  Endo isomer: IR
(film) 3429, 2974, 2927, 2850, 2781, 2734, 1908, 1722, 1599, 1490, 1460, 1375, 1344, 1298,
1205, 1089, 1020, 911.4, 818.7, 679.7 cm-1; 1H NMR (400 MHz, CDCl3) d  9.74 (d, J  = 2.3 Hz,
1H, CHO), 7.25-7.33 (m, 4H, ArH), 4.51 (dq, J d = 5.9, J q = 6.1 Hz, 1H, CH H3),  3.82-4.01 (m,
1H, CHC6H4Cl), 3.02 (ddd, J  = 8.0, 5.5, 2.3 Hz, 1H, CCHO), 2.59 (s, 3H, NCH3), 1.55 (d, J  =
6.2 Hz, 3H, CHCH3); 
13C NMR (125 MHz, CDCl3) d  198.3, 136.7, 134.3, 129.6, 129.5, 129.3,
129.1, 73.5, 73.1, 72.2; LRMS (FAB) m/z 239 (M)+; HRMS (FAB) exact mass calcd for
(C12H14ClNO2) requires m/z 239.0713, found m/z 239.0707 (M)
+; [a ]D = +64.1 ° (c = 1.0, CHCl3).
Diastereomeric ratios were determined by 1H NMR analysis.  A portion of the title compound
was reduced to the corresponding primary alcohol (general procedure C) and purified by silica
gel chromatography (2:3 EtOAc/hexane) for the determination of enantiomeric purity; endo 94%
ee.  1H NMR (300 MHz, CDCl3) d  7.24-7.38 (m, 4H, ArH), 4.20 (dq, J d = 6.2, J q = 6.0, 1H,
CHON), 3.66-3.75 (m, 2H, C2OH), 3.35 (d, J  = 8.52 Hz, 1H, CH 6H4Cl), 2.28-2.34 (m, 1H,
CHCH2OH), 1.43 (d, J  = 6.3 Hz, 3H, CH3).  Enantiomeric ratios were determined by HPLC with
a Chiralcel OD-H column and OD guard column (3:97 iPrOH/hexane, 1 mL/min flow rate); endo
isomers tr = 29.0 min and 45.3 min.
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(3R,4S,5R)-2-Benzyl-4-formyl-5-methyl-3-(4-methoxyphenyl) isoxazolidine (Table 3,
entry 6).  Prepared according to general procedure B (Z)-N-para-
methoxybenzylidenebenzylamine N-oxide (72 mg, 0.30 mmol), (5S)-5-Benzyl-2,2,3-
trimethylimidazolidin-4-one perchloric acid salt (8) (19 mg, 0.06 mmol), crotonaldehyde (100
m L, 1.2 mmol followed by 5 x 75 m L, 0.90 mmol, over 24 h intervals) and H2O (16 m L, 0.90
mmol) in CH3NO2 (3.0 ml) at  –20 ˚C over the course of 136 h.  The resulting solution was
passed through a silica gel column with CH2Cl2 to provide the title compound as an oil in 93%
yield (86 mg); 98:2 endo:exo.  Endo isomer: IR (film) 3429, 3035, 2974, 2935, 2835, 2726,
1722, 1614, 1514, 1452, 1375, 1298, 1251, 1174, 1035, 826, 734, 703 cm-1; 1H NMR ( 00 MHz,
CDCl3) d  9.76 (d, J  = 2.5 Hz, 1H, CHO), 7.23–7.38 (m, 7H, ArH), 6.87-6.91 (m, 2H, ArH), 4.52
(m, 1H, CHCH3), 4.06 (d, J  = 8.2 Hz, 1H, CH 6H4OCH3), 3.99 (d, J  = 14.3 Hz, 1H, CH2C6H5),
3.80 (s, 3H, OCH3), 3.76 (d, J  = 14.6 Hz, 1H, CH2 6H5), 3.08 (ddd, J  = 8.0, 5.5, 2.5 Hz, 1H,
CHCHO), 1.50 (d, J  = 6.3 Hz, 3H, CHC3); 
13C NMR (125 MHz, CDCl3) d  199.1, 159.8, 137.7,
130.1, 129.1, 128.7, 128.5, 137.4, 114.6, 73.6, 71.8, 71.2, 59.5, 55.6, 21.5; LRMS (CI) m/z 311
(M)+; HRMS (CI) exact mass calcd for (C19H21NO3) requires m/z 311.1521, found m/z311.1514
(M)+; [a ]D = +71.8 ° (c = 1.0, CHCl3).  Diastereomeric ratios were determined by 
1H NMR
analysis.  A portion of the title compound was reduced to the corresponding primary alcohol
(general procedure C) and purified by silica gel chromatography (3:7 EtOAc/hexane) for the
determination of enantiomeric purity; endo 91% ee. 1H NMR (500 MHz, CDCl3) d  7.17–7.41 (m,
7H, ArH), 6.86-6.93 (m, 2H, ArH), 4.17 (dq, J d = 5.9, J q = 6.0, 1H, CHON), 3.96 (d, J  = 14.6
Hz, 1H, CH2C6H5), 3.80 (s, 3H, OCH3), 3.73 (d, J  = 14.3 Hz, 1H, CH2 6H5), 3.69-3.73 (m, 2H,
CH2OH), 3.56 (d, J  = 8.5 Hz, 1H, CH 6H4OCH3), 2.29-2.38 (m, 1H, CCH2OH), 1.43 (d, J  =
6.0 Hz, 3H, CH3).  Enantiomeric ratios were determined by HPLC with a Chiralcel AD column
and AD guard column (3:97 EtOH/hexane, 1 mL/min flow rate); endo isomers tr = 37.7 min and
69.5 min.
(3R,4S,5R)-2,5-Dimethyl-4-formyl-3-(4-tolyl) isoxazolidine (Table 3, entry 7).
Prepared according to general procedure B from (Z)-N-para-methylbenzylidenemethylamine N-
oxide (60 mg, 0.40 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt
(8) (26 mg, 0.08 mmol), crotonaldehyde (133 m L, 1.6 mmol followed by 7 x 100 m L, 1.20 mmol,
over 24 h intervals) and H2O (22 m L, 1.20 mmol) in CH3NO2 (4.0 ml) at  –20 ˚C over the course
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of 160 h.  The resulting solution was passed through a silica gel column with CH2C 2 to provide
the title compound as an oil in 82% yield (72 mg); 93:7 endo:exo.  Endo isomer: IR (film) 3429,
2974, 2927, 2873, 2726, 1722, 1514, 1452, 1375, 1344, 1112, 1066, 911, 811, 687 cm-1; 1H
NMR (300 MHz, CDCl3) d  9.74 (d, J = 2.5 Hz, 1H, CHO), 7.12-7.26 (m, 4H, ArH), 4.53 (dq, J d
= 5.9, J q = 6.3 Hz, 1H, CH H3), 3.78 (bs, 1H, CH 6H4CH3), 3.09 (ddd, J  = 8.4, 5.4, 2.5 Hz, 1H,
CHCHO), 2.59 (s, 3H, NCH3), 2.34 (s, 3H, C6H4CH3), 1.51 (d, J  = 6.3 Hz, 3H, CHC3); 
13C
NMR (125 MHz, CDCl3) d  198.7, 138.3, 134.5, 130.0, 129.6, 128.0, 127.5, 73.6, 72.2, 43.7,
21.6; LRMS (CI) m/z 219 (M)+; HRMS (CI) exact mass calcd for (C13H17NO2) requires m/z
219.1259, found m/z219.1262 (M)+; [a ]D = +67.9 ° (c = 1.0, CHCl3).  Diastereomeric ratios were
determined by 1H NMR analysis.  A portion of the title compound was reduced to the
corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 97% ee. 1H NMR (300
MHz, CDCl3) d  7.13-7.26 (m, 4H, ArH), 4.20 (dq, J d = 6.2, J q = 6.0 Hz, 1H, CHON), 3.63-3.71
(m, 2H, CH2OH), 3.29 (d, J = 7.7 Hz, 1H, CC6H4CH3), 2.55 (s, 3H, NCH3), 2.33 (s, 3H,
C6H4CH3), 2.31-2.39 (m, 1H, CHCH2OH), 1.44 (d, J  = 6.0 Hz, 3H, CHC3).  Enantiomeric
ratios were determined by HPLC with a Chiralcel AD column and AD guard column (3:97
iPrOH/hexane, 1 mL/min flow rate); endo isomers tr = 40.2 min and 47.6 min.
(3R,4S,5R)-2-Benzyl-4-formyl-5-methyl-3-(2-napthyl) isoxazolidine (Table 3, entry
8).  Prepared according to general procedure B from (Z)-N-2-napthylidenebenzylamine N-oxide
(78 mg, 0.30 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid salt (8)
(19 mg, 0.06 mmol), crotonaldehyde (100 m L, 1.2 mmol followed by 5 x 75 m L, 0.90 mmol, over
24 h intervals) and H2O (16 m L, 0.90 mmol) in CH3NO2 (3.0 ml) at  –20 ˚C over the course of
138 h.  The resulting solution was passed through a silica gel column with CH2Cl2 to provide the
title compound as an oil in 98% yield (97 mg); 95:5 endo:exo.  Endo isomer: IR (film) 3429,
3059, 2981, 2927, 2866, 2726, 1954, 1722, 1607, 1498, 1452, 1375, 1313, 1120, 819, 742, 703
cm-1; 1H NMR (400 MHz, CDCl3) d  9.83 (d, J = 2.3 Hz, 1H, CHO), 7.84-7.89 (m, 5H, ArH),
7.61 (dd, J  = 1.6 Hz, 1H, ArH), 7.49-7.52 (m, 2H, ArH), 7.24–7.38 (m, 2H, ArH), 4.61 (dq, J d =
5.9, J q = 6.1 Hz, 1H, CH H3), 4.35 (d, J  = 7.7 Hz, 1H, CHNapth), 4.06 (d, J  = 14.3 Hz, 1H,
CH2C6H5), 3.89 (d, J  = 14.3 Hz, 1H, CH2 6H5), 2.20 (ddd, J  = 7.8, 5.5, 2.3 Hz, 1H, CCHO),
1.55 (d, J = 6.2 Hz, 3H, CHC3); 
13C NMR (125 MHz, CDCl3) d  198.8, 137.5, 136.0, 133.5,
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133.4, 129.1, 128.7, 128.4, 128.1, 127.9, 137.4, 127.1, 126.6, 126.5, 125.1, 73.8, 71.6, 71.5, 59.8,
21.3; LRMS (CI) m/z 331 (M)+; HRMS (FAB) exact mass calcd for (C22H21NO2) requires m/z
331.1572, found m/z331.1567 (M)+; [a ]D = +53.1 ° (c = 1.0, CHCl3).  Diastereomeric ratios were
determined by 1H NMR analysis.  A portion of the title compound was reduced to the
corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 93% ee. 1H NMR (500
MHz, CDCl3) d  7.84–7.86 (m, 4H, ArH), 7.66-7.67 (m, 1H, ArH), 7.48-7.52 (m, 2H, ArH),
7.20-7.40 (m, 5H, ArH), 4.28 (dq, J d = 6.1, J q = 5.9, 1H, CHON), 4.04 (d, J  = 14.2 Hz, 1H,
CH2C6H5), 3.75-3.87 (m, 4H, CH2 6H5, CH2OH, CHNapth), 2.46-2.51 (m, 1H, CHCH2OH),
1.50 (d, J = 5.9 Hz, 3H, CH3).  Enantiomeric ratios were determined by HPLC with a Chiralcel
AD column and AD guard column (1:39 EtOH/hexane, 1 mL/min flow rate); endo isom rs tr =
57.7 min and 107.6 min.
(3R,4S,5R)-2-Benzyl-4-formyl-5-methyl-3-cyclohexyl isoxazolidine (Table 3, entry
9).  Prepared according to general procedure A from (Z)-N-cyclohexylmethylidenebenzylamine
N-oxide (65 mg, 0.30 mmol), (5S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one perchloric acid
salt (8) (19 mg, 0.06 mmol), crotonaldehyde (200 m L) and H2O (16 m L, 0.90 mmol) in CH3 N
(3.0 ml) at –40 ˚C over the course of 96 h.  The resulting solution was passed through a silica gel
column with CH2Cl2 and purified by silica gel chromatography (2:23 EtOAc/Hexane) to provide
the title compound as an oil in 69% yield (59 mg); 99:1 endo:exo.  Endo isomer: IR (film) 2927,
2858, 2719, 1722, 1498, 1452, 1383, 1328, 1074, 1027, 973, 703 cm-1; 1H NMR (300 MHz,
CDCl3) d  9.80 (d, J  = 3.0 Hz, 1H, CHO), 7.23-7.40 (m, 5H, ArH), 4.57-4.64 (dq, J d = 7.7, J q =
6.1 Hz, 1H, CHON), 4.08 (d, J  = 13.5 Hz, 1H, CH2 6H5), 3.82 (d, J  = 13.2 Hz, 1H, CH2C6H5),
3.05 (dd, J = 7.7, 5.5 Hz, 1H, CH-chex), 2.86-2.91 (m, 1H, CHCHO), 1.35 (d, J  = 6.1 Hz, 3H,
CHCH3), 0.70-2.03 (m, 11H, chex-H); 
13C NMR (75 MHz, CDCl3) d  73.6, 72.8, 67.2, 62.0, 42.6,
30.9, 29.8, 26.7, 26.3, 26.2, 18.1; LRMS (EI) m/z287 (M)+; HRMS (EI) exact mass calcd for
(C18H25NO2) requires m/z 287.1885, found m/z287.1881 (M)
+; [a ]D = +48.6 ° (c = 1.0, CHCl3).
Diastereomeric ratios were determined by 1H NMR analysis.  A portion of the title compound
was reduced to the corresponding primary alcohol (general procedure C) and purified by silica
gel chromatography (3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 99%
ee. 1H NMR (300 MHz, CDCl3) d  7.32-7.41 (m, 5H, ArH), 4.32-4.34 (m, 1H, CON), 4.14 (d, J
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= 12.7 Hz, 1H, CH2C6H5), 3.88 (d, J  = 13.2 Hz, 1H, CH2 6H5), 3.73-3.84 (m, 2H, C2OH), 2.58
(dd, J = 6.1, 5.4 Hz, 1H, C-chex), 2.14-2.18 (m, 1H, CHCH2OH), 1.34 (d, J  = 6.4 Hz, 3H,
CHCH3), 0.82-1.74 (m, 11H, chex-H).  Enantiomeric ratios were determined by HPLC with a
Chiralcel OD-H column and OD guard column (3:97 iPrOH/hex, 1 mL/min flow rate); end
isomers tr = 22.9 min and 26.7 min.
(3R,4S)-2-Benzyl-4-formyl-3-phenylisoxazolidine (Table 3, entry 11).  Prepared
according to general procedure A from (Z)-N-benzylidenebenzylamine N-oxide (63 mg, 0.30
mmol), (5S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one trifluoromethanesulfonic acid salt (5)
(22 mg, 0.06 mmol), acrolein (71 m L, 1.2 mmol) and H2O (16 m L, 0.90 mmol) in CH3NO2 (3.0
ml) at –18 ˚C over the course of 120 h to provide the title compound as a colorless oil in 80%
yield (63 mg); 86:14 endo:exo.  Endo isomer:  IR (CH2Cl2) 2873, 1722, 1498, 1452, 1050 cm
-1;
1H NMR (400 MHz, CDCl3) d  9.80 (d, J = 2.1 Hz, 1H, CHO), 7.27–7.51 (m, 10H, C6H5 and
CH2C6H5), 4.27–4.30 (m, 2H, C2ON), 4.07 (d, J  = 7.1 Hz, 1H, CH 6H5), 3.99 (d, J  = 14.2 Hz,
1H, CH2C6H5), 3.78 (d, J  = 14.2 Hz, 1H, CH2 6H5), 3.44 (m, 1H, CH HO); 
13C NMR (100
MHz, CDCl3) d  198.4, 138.1, 137.1, 128.9, 128.6, 128.3, 128.2, 127.8, 127.3, 70.6, 65.8, 64.3,
59.6; LRMS (CI) m/z 267 (M)+; HRMS (CI) exact mass calcd for (C17H17NO2) requires m/z
267.1259, found m/z267.1268;  [a ]D = +43.4 ° (c = 1.0, CHCl3).  Diastereomeric ratios were
determined by 1H NMR analysis.  A portion of the title compound was reduced to the
corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 92% ee. 1H NMR (300
MHz, CDCl3) d  7.19–7.51 (m, 10H, C6H5 and CH2C6H5), 4.19 (dd, J  = 8.2, 8.2 Hz, 1H, CH2ON),
3.94 (d, J = 14.3 Hz, 1H, CH2 6H5), 3.88–3.92 (dd, J  = 4.4, 8.2 Hz, 1H, C2ON), 3.65–3.83 (m,
2H, CH2OH), 3.70 (d, J  = 14.0 Hz, 1H, CH2 6H5), 3.47 (d, J  = 7.7 Hz, 1H, CH 6H5), 2.72–2.83
(m, 1H, CHCH2OH).  Enantiomeric ratios were determined by HPLC with a Chiralcel AD
column (1:24 EtOH/hexane,  1 mL/min flow rate); endo isomers tr = 15.8 min and 20.4 min.
(3R,4S)-2-Benzyl-4-formyl-3-(4-methylphenyl)isoxazolidine (Table 3, entry 12).
Prepared according to general procedure B from (Z)-N-para-methylbenzylidenebenzylamine N-
oxide (72 mg, 0.30 mmol), (5S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one
trifluoromethanesulfonic acid salt (5) (22 mg, 0.06 mmol), acrolein (71 m L, 1.2 mmol followed
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by 4 x 36 m L, 0.60 mmol, over 24 h intervals), H2O (16 m L, 0.90 mmol), and in CH3NO2 (3.0 ml)
at  –18 ˚C over the course of 112 h to provide the title compound as a colorless oil in 80% yield
(66 mg) after silica gel chromatography (17:83 EtOAc/hexane); 85:15 endo:exo.  Endo isomer:
IR (CH2Cl2) 2873, 1722, 1514, 1050 cm
-1; 1H NMR (300 MHz, CDCl3) d  9.77 (d, J  = 2.2 Hz, 1H,
CHO), 7.19–7.47 (m, 7H, C6H4 H3 and CH2C6H5), 4.24–4.28 (m, 2H, C2ON), 3.97–4.02 (m,
2H, CHNO and CH2C6H5), 3.75 (d, J  = 14.0 Hz, 1H, CH2C6H5), 3.38–3.46 (m, 1H, CCHO),
2.39 (s, 3H, C6H4CH3); 
13C NMR (100 MHz, CDCl3) d  199.1, 138.4, 137.5, 135.0, 129.9, 128.9,
128.5, 128.0, 127.5, 70.9, 66.2, 64.6, 59.9, 21.6; LRMS (CI) m/z  281 (M)+; HRMS (CI) exact
mass calcd for (C18H19NO2) requires m/z 281.1416, found m/z 281.1415; [a ]D = +39.8 ° (c = 1.0,
CHCl3).  Diastereomeric ratio was determined by 
1H NMR analysis.  A portion of the title
compound was reduced to the corresponding primary alcohol (general procedure C) and purified
by silica gel chromatography (3:7 EtOAc/hexane) for the determination of enantiomeric purity;
endo 90% ee.  1H NMR (300 MHz, CDCl3) d  7.16–7.37 (m, 9H, C6H4CH3 and CH2C6H5), 4.18
(dd, J  = 8.2, 8.2 Hz, 1H, CH2ON), 3.94 (d, J  = 14.8 Hz, 1H, CH2 6H5), 3.87-3.91 (dd, J  = 4.3,
8.1 Hz, 1H, CH2ON), 3.67–3.82 (m, 2H, C2OH), 3.65 (d, J  = 14.3 Hz, 1H, CH2 6H5), 3.44 (d,
J  = 7.7 Hz, 1H, CH 6H4CH3), 2.70–2.81 (m, 1H, CHCH2OH), 2.35 (s, 3H, C6H4CH3).
Enantiomeric ratios were determined by HPLC with  Chiralcel AD column and AD guard
column (1:9 EtOH/hexane, 1 mL/min flow rate); endo isomers tr = 9.1 min and 10.0 min.
(3R,4S)-2-Benzyl-4-formyl-3-(4-chlorophenyl)isoxazolidine (Table 3, entry 13).
Prepared according to general procedure B from (Z)-N-para-chlorobenzylidenebenzylamine N-
oxide (74 mg, 0.30 mmol), (5S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one
trifluoromethanesulfonic acid salt (5) (22 mg, 0.06 mmol), acrolein (71 m L, 1.2 mmol followed
by 3 x 36 m L, 0.60 mmol, over 24 h intervals) and H2O (16 m L, 0.90 mmol) in CH3NO2 (3.0 ml)
at –18 ˚C over the course of 96 h to provide the title compound as a colorless oil in 80% yield
(70 mg) after silica gel chromatography (1:4 EtOAc/hexane); 80:20 endo:exo.  Endo isomer: IR
(CH2Cl2) 2881, 1722, 1599, 1491 cm
-1; 1H NMR (400 MHz, CDCl3) d  9.78 (d, J = 2.0 Hz, 1H,
CHO), 7.26–7.44 (m, 9H, C6H4 l and CH2C6H5), 4.27–4.29 (m, 2H, C2ON), 4.08 (d, J  = 7.0
Hz, 1H, CHC6H4Cl), 3.96 (d, J  = 14.0 Hz, 1H, CH2C6H5), 3.80 (d, J  = 14.2 Hz, 1H, CH2 6H5),
3.34–3.40 (m, 1H, CHCHO); 13C NMR (100 MHz, CDCl3) d  198.4, 136.8, 134.0, 136.7, 129.1,
128.7, 128.2, 127.4, 129.1, 69.6, 65.8, 64.3, 59.7; LRMS (CI) m/z  (M); HRMS (CI) exact mass
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calcd for (C17H16ClNO2) requires m/z 301.0870 (M)
+, found m/z 301.0862; [a ]D = +36.5 ° (c =
1.0, CHCl3).  Diastereomeric ratios were determined by 
1H NMR analysis.  A portion of the title
compound was reduced to the corresponding primary alcohol (general procedure C) and purified
by silica gel chromatography (2:3 EtOAc/hexane) for the determination of enantiomeric purity;
endo 91% ee.  1H NMR (300 MHz, CDCl3) d  7.04–7.42 (m, 9H, C6H4Cl and CH2C6H5), 4.17 (dd,
J  = 8.2, 8.2 Hz, 1H, CH2ON), 3.91 (d, J  = 14.0 Hz, 1H, CH2 6H5), 3.86–3.90 (dd, J  = 4.7, 8.2
Hz, 1H, CH2ON), 3.72–3.78 (m, 2H, C2OH), 3.72 (d, J  = 14.0 Hz, 1H, CH2 6H5), 3.49 (d, J  =
7.7 Hz, 1H, CHC6H4Cl), 2.68–2.76 (m, 1H, CCH2OH).  Enantiomeric ratios were determined
by HPLC with a Chiralcel AD column and AD guard column (1:19 iPrOH/hexane, 1 mL/min
flow rate); endo isomers tr = 20.7 min and 23.5 min.
(3R,4S)-2-Benzyl-4-formyl-3-napthylisoxazolidine (Table 3, entry 14).  Prepared
according to general procedure A from (Z)-N-2-napthylidenebenzylamine N-oxide (78 mg, 0.30
mmol), (5S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one trifluoromethanesulfonic acid salt (5)
(22 mg, 0.06 mmol), acrolein (71 m L, 1.2 mmol), H2O (16 m L, 0.90 mmol), and in CH3NO2 (3.0
ml) at –18 ˚C over the course of 112 h to provide the title compound as a colorless oil in 82%
yield (75 mg) after silica gel chromatography (1:3 EtOAc/hexane); 81:19 endo:exo.  Endo
isomer: IR (CH2Cl2) 3059, 2835, 1722, 1498, 1607 cm
-1; 1H NMR (400 MHz, CDCl3) d  9.83 (d, J
= 2.0 Hz, 1H, CHO), 7.27–7.95 (m, 12H, C10H7 and CH2C6H5), 4.32–4.36 (m, 2H, CH2ON),
4.28 (d, J = 7.0 Hz, 1H, CH 10H7), 4.01 (d, J  = 14.1 Hz, 1H, CH2C6H5), 3.85 (d, J  = 14.2 Hz,
1H, CH2C6H5), 3.53 (m, 1H, CH HO); 
13C NMR (100 MHz, CDCl3) d  198.7, 137.1, 135.4,
133.3, 133.2, 128.9, 128.7, 128.2, 127.9, 127.8, 127.7, 127.3, 127.2, 126.4, 126.3, 125.0, 110.4,
70.8, 65.9, 64.2, 59.7; LRMS (CI) m/z  317 (M)+; HRMS (CI) exact mass calcd for (C21H19NO2)
requires m/z 317.1416, found m/z317.1416; [a ]D = +20.3 ° (c = 1.0, CHCl3).  Diastereomeric
ratio was determined by  1H NMR analysis. A portion of the title compound was reduced to the
corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(3:7 EtOAc/hexane) for the determination of enantiomeric purity; endo 90% ee. 1H NMR (300
MHz, CDCl3) d  7.21–7.89 (m, 12H, C10H7 and CH2C6H5), 4.26 (dd, J  = 8.2, 8.2 Hz, 1H,
CH2ON), 3.98 (d, J  = 14.0 Hz, 1H, CH2C6H5), 3.93–3.98 (dd, J  = 4.6, 8.2 Hz, 1H, CH2ON), 3.75
(d, J  = 14.0, 1H, CH2C6H5), 3.72–3.83 (m, 2H, CH2O ), 3.67 (d, J  = 7.7 Hz, 1H, CH 10H7),
2.82–2.93 (m, 1H, CHCH2OH).  Enantiomeric ratios were determined by HPLC with  Chiralcel
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AD column and AD guard column (1:9 EtOH/hexane, 1 mL/min flow rate); endo isom rs tr =
12.7 min and 17.5 min.
(3R,4S)-2-Benzyl-4-formyl-3-(4-methoxyphenyl)isoxazolidine (Table 3,  entry 15).
Prepared according to general procedure B from (Z)-N-para-methoxybenzylidenebenzylamine
N-oxide (72 mg, 0.30 mmol), (5S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one
trifluoromethanesulfonic acid salt (5) (22 mg, 0.06 mmol), acrolein (71 m L, 1.2 mmol followed
by 3 x 36 m L, 0.60 mmol, over 24 h intervals), H2O (16 m L, 0.90 mmol), and in CH3NO2 (3.0 ml)
at  –18 ˚C over the course of 87 h to provide the title compound as a colorless oil in 83% yield
(73 mg) after silica gel chromatography (3:7 EtOAc/hexane); 91:9 endo:exo.  Endo isomer: IR
(CH2Cl2) 2935, 1722, 1614, 1514, 1460, 1251 cm
-1; 1H NMR (400 MHz, CDCl3) d  9.77 (d, J =
2.1 Hz, 1H, CHO), 7.26–7.42 (m, 7H, C6H4OCH3 and CH2C6H5), 6.94 (d, J  = 8.7 Hz, 2H, ortho
C6H4OCH3), 4.22–4.28 (m, 2H, C2ON), 3.96–4.00 (m, 2H, CNO and CH2C6H5), 3.82 (s, 3H,
OCH3), 3.73 (d, J  = 14.2 Hz, 1H, CH2 6H5), 3.40 (m, 1H, CH HO); 
13C NMR (100 MHz,
CDCl3) d  198.9, 159.6, 137.3, 129.6, 129.0, 128.6, 128.2, 127.2, 114.3, 70.3, 65.8, 64.1, 59.4,
55.2; LRMS (CI) m/z 297 (M)+; HRMS (CI) exact mass calcd for (C18H19NO3) requires m/z
297.1365, found m/z 297.1361. [a ]D = +31.9 ° (c = 1.0, CHCl3). Diastereomeric ratio was
determined by 1H NMR analysis. A portion of the title compound was reduced to the
corresponding primary alcohol (general procedure C) and purified by silica gel chromatography
(2:3 EtOAc/hexane) for the determination of enantiomeric purity; endo 90% ee.  1H NMR (300
MHz, CDCl3) d  7.19–7.40 (m, 7H, C6H4OCH3 and CH2C6H5), 6.92 (d, J = 1.9 Hz, 2H,
C6H4OCH3), 4.16 (dd, J  = 8.2, 8.2 Hz, 1H, CH2ON), 3.90 (d, J  = 14.3 Hz, 1H, CH2C6H5), 3.87
(dd, J  = 4.4, 8.2 Hz, 1H, CH2ON), 3.81 (s, 3H, C6H4OCH3), 3.66–3.79 (m, 2H, C2OH), 3.65 (d,
J  = 14.3 Hz, 1H, CH2 6H5), 3.42 (d, J = 7.6 Hz, 1H, CH 6H5OCH3), 2.69–2.80 (m, 1H,
CHCH2OH).   Enantiomeric ratios were determined by HPLC with Chiralcel AD column and
AD guard column (2:23 iPrOH/hexane, 1 mL/min flow rate); endo isomers tr = 15.4 min and
17.0 min.
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Determination of the absolute configuration of (3R,4S,5R)-2-benzyl-4-formyl-5-
methyl-3-phenylisoxazolidine (Table 3, entry 1) by correlation with (3R,4S,5R)-2-benzyl-5-
methyl-3-phenylisoxazolidine-4-carboxylic acid isopropyl ester.
Me O
N
O
Bn
Ph
+
-
+
N
H
N
O
Ph
HClO4
20 mol%, -20 °C,
CH3NO2–H2O
N O
Bn
MePh
CHO
Me O
N
O
Bn
Ph
+
-
+
HCl
20 mol%, 25 °C,
CH3NO2–H2O
N O
Bn
MePh
CHO
N
H
CO2Me
1. NaClO2, NaH2PO4, 
     2-methyl-2-butene,
      H2O, t-BuOH
2. DCC, DMAP, i-PrOH
      CH2Cl2
N O
Bn
MePh
CO2i-Pr
[a ] (found) = -7.4 °
[a ] (lit.4) = -28.1 °
N O
Bn
MePh
NaBH4
EtOH
HPLC: t1 = 59.3 (minor enantiomer)
       t2 = 76.3 (major enantiomer)
OH
41% ee
94% ee
Table 3, entry 1
N O
Bn
MePh
OH
HPLC: t1 = 59.3 (major enantiomer)
       t2 = 76.3 (minor enantiomer)
NaBH4
EtOH
According to general procedure B, a solution of (Z)-N-benzylidenebenzylamine N-oxide
(105.6 mg, 0.50 mmol), (2S -proline methyl ester hydrochloric acid salt (20.3 mg, 0.10 mmol),
crotonaldehyde (0.13 mL, 1.50 mmol) and H2O (5.0 m L, 0.09 mmol) in CH3NO2 (5.0 mL) was
added to (3S,4R,5S)-2-Benzyl-4-formyl-5-methyl-3-phenylisoxazolidine, and the reaction was
stirred for 24 h.  The resulting solution was passed through a silica gel column with CH2Cl2 to
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provide (3S,4R,5S)-2-Benzyl-4-formyl-5-methyl-3-phenylisoxazolidine.  A portion of this
product was reduced to the corresponding primary alcohol (general procedure C) and purified by
silica gel chromatography (3:7 EtOAc/hexane) for the determination of enantiomeric purity;
endo 41% ee. Enantiomeric ratios were determined by HPLC with a Chiralcel OD-H column and
OD guard column (1:39 iPrOH/hexane, 1 mL/min flow rate); endo isomers tr = 59.3 min (minor
enantiomer) and 76.3 min (major enantiomer).  The remainder of the product (59.4 mg, 0.21
mmol) was dissolved in tert-butanol (4.4 mL).  To this solution was added 2-methyl-2-butene (1
mL, 90 mmol) and, dropwise, a solution of NaClO2 (175 mg, 1.93 mmol) and NaH2PO4 (203 mg,
1.47 mmol) in H2O (1.8 mL).  The biphasic solution was stirred for 11 h.  The reaction was
concentrated, diluted with H2O (25 mL), and washed with hexanes (25 mL).  The aqueous layer
was acidified with 1N HCl to pH 2, and extracted with Et2O (2 x 30 mL).  The combined organic
layers were washed with cold H2O (15 mL), dried (Na2SO4), and concentrated.  To this oil was
added CH2Cl2 (0.75 mL), 4-dimethylamino-pyridine (1.0 mg, 0.008 mmol), and 2-propanol
(0.023 mL, 0.3 mmol).  This solution was added to dicyclohexylcarbodiimide (19.3 mg, 0.09
mmol) and the reaction was stirred for 2 h at which time the mixture was filtered and
concentrated.  The resulting residue was taken up in CH2Cl2 (10 mL) and filtered again.  The
filtrate was then washed sequentially with 0.5N HCl (10 mL) and sat. aq. NaHCO3 (10 mL),
dried (Na2SO4), and concentrated.  The resulting residue was purified by silica gel
chromatography (1:9 EtOAc/hexane) to afford an oil that was identical in all respects to the
compound (3S,4R,5S)-2-benzyl-4-formyl-5-methyl-3-phenylisoxazolidine isopropyl ester;4 [a ]D
(literature) = –28.1 ° (c = 1.0, CHCl3); [a ]D (found) = –7.4 ° (c = 1.0, CHCl3).
(1R,2R,3R)-1-(Benzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol.  Following
general procedure C, (3R 4S,5R)-2-benzyl-4-formyl-5-methyl-3-phenylisoxazolidine (Table 3,
entry 1) (25.0 mg, 0.09 mmol), of known absolute configuration (vide supra), was reduced to the
corresponding primary alcohol and purified by silica gel chromatography (3:7 EtOAc/hexane).
The resulting oil was dissolved in EtOH (1.2 mL) and heated to reflux.  Sodium metal (180 mg,
7.83 mmol) was added in 25 mg portions to the solution.  Upon formation of a white solid (2.5
h), the reaction was cooled to room temperature and added to H2O (5 mL).  The resulting mixture
was diluted with EtOAc (10 mL), washed with NH4Cl (5 mL), and then extracted with EtOAc (3
                                                
4 Gothelf, K. V., Thomsen, I., Jørgensen, K. A., J. Am  Chem. Soc., 1996, 118, 59-64.
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x 10 mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.  Purification
of the resulting oil by silica gel chromatography (1:39 Et3N/EtOAc) afforded (1R,2R,3R)-1-
(benzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol as a white solid: 1H NMR (300 MHz,
CDCl3) d  7.42–7.20 (m, 10H, C6H5),  4.07 (dq, J = 2.2, 6.0 Hz, 1H, CHCH3),  3.99 (d, J  = 9.3
Hz, 1H, NCHC6H5), 3.60 (d, J  = 12.6 Hz, 1H, CH2 6H5), 3.54 (d, J  = 12.6 Hz, 1H, CH2 6H5),
3.52 (dd, J = 3.9, 11.3 Hz, 1H, CH2OH), 3.19 (dd, J  = 3.3, 11.3 Hz, 1H, C2OH), 1.74-1.66 (m,
1H, CHCH2OH), 1.25 (d, J  = 6.3 Hz, 3H, CH3); 
13C NMR (100 MHz, CDCl3) d  141.4, 139.0,
129.1, 128.8, 127.9, 127.6, 127.5, 69.6, 64.9, 61.6, 51.9, 51.7, 22.3; [a ]D = +41 5 ° (c = 1.0,
CHCl3).
Determination of the absolute configuration of (3R,4S,5R)-2-allyl-4-formyl-5-
methyl-3-phenylisoxazolidine (Table 3, entry 2) by correlation with (1R,2R,3R)-1-
(allylbenzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol.
To a solution of (1R,2R,3R)-1-(Benzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol
(23.0 mg, 0.08 mmol), of known absolute configuration (vide supra) and K2CO3 (44.8 mg, 0.32
mmol) in 1 : 1 H2O : CH3CN (0.5 mL : 0.5 mL), was added allyl bromide (0.05 mL, 0.32 mmol),
and the resulting solution was stirred for 63 h.  The reaction was extracted with Et2O (3 x 10
mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.  The resulting oil
was purified by silica gel chromatography (2:3 EtOAc/hexane) to afford (1R,2R,3R)-1-
(allylbenzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol: 1H NMR (500 MHz, CDCl3) d
7.45–7.21 (m, 10H, C6H5),  5.93–5.87 (m, 1H, CH2=C CH2), 5.25–5.21 (m, 2H, CH2=CH),
4.17-4.10 (m, 1H, CHCH3),  4.07 (d, J  = 11.2 Hz, 1H, NCH 6H5), 4.02 (d, J  = 13.7 Hz, 1H,
CH2C6H5), 3.55-3.49 (m, 2H, C2OH, CH2=CHCH2N), 3.31 (dd, J  = 3.4, 11.3 Hz, 1H, C2OH),
2.95 (d, J = 13.7 Hz, 1H, CH2C6H5), 2.55 (dd, J  = 8.8, 13.2 Hz, 1H, CH2=CHCH2N), 2.26-2.22
(m, 1H, CHCH2OH), 1.33 (d, J  = 6.3 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3) d  138.5, 135.7,
133.9, 130.1, 129.4, 128.9, 128.5, 128.0, 127.6, 119.1, 70.2, 65.0, 61.8, 54.4, 53.1, 46.1, 21.2;
[a ]D = +74.3 ° (c = 1.0, CHCl3).
A solution of (3R,4S,5R)-2-allyl-4-formyl-5-methyl-3-phenylisoxazolidine (Table 3,
entry 2) (51.0 mg, 0.22 mmol) was reduced to the corresponding primary alcohol (general
procedure C) and purified by silica gel chromatography (3:7 EtOAc/hexane).  The resulting oil
(24.8 mg, 0.11 mmol) was dissolved in EtOH (3.5 mL) and heated to reflux.  Sodium metal (150
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mg,  6.52 mmol) was added in 25 mg portions to the solution.  Upon formation of a white solid
(3 h), the reaction was cooled to room temperature and added to H2O (5 mL).  The resulting
mixture was diluted with EtOAc (10 mL), washed with NH4Cl (5 mL), and then extracted with
EtOAc (3 x 10 mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.
Purification of the resulting oil by silica gel chromatography (4:21 Et3N/EtOAc) afforded a white
solid.  The solid (5.4 mg, 0.023 mmol) was dissolved in CH3CN (1.0 mL).  To the stirring
solution was added benzyl bromide (3.0 m L, 0. 25 mmol) and K2CO3 (5.7 mg, 0.041 mmol).
The reaction was heated to reflux for 12 hours.  The solution was then filtered and concentrated.
The resulting residue was purified by silica gel chromatography (1:1 EtOAc/hexane) to afford a
an oil that was identical in all respects to the compound (1R,2R,3R)-1- allylbenzylamino)-2-
(hydroxymethyl)-1-phenyl-butan-3-ol (vide supra); [a ]D = +72. 1 ° (c = 1.0, CHCl3).
Determination of the absolute configuration of (3R,4S,5R)-2,5-dimethyl-4-formyl-3-
phenylisoxazolidine (Table 3, entry 3) by correlation with (1R,2R,3R)-1-
(benzylmethylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol.
To a solution of (1R,2R,3R)-1-(benzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol
(26.8 mg, 0.09 mmol), of known absolute configuration (vide supra), and K2CO3 (52.0 mg, 0.38
mmol) in CH3CN (1.5 mL) was added iodomethane (5.8 m L, 0 09 mmol) and the resulting
mixture was stirred for 48h.  The reaction was diluted with H2O (10 mL) and extracted with
EtOAc (3 x 10 mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.
The resulting oil was purified by silica gel chromatography (1:1 EtOAc/hexane) to afford (1R,
2R, 3R)-1-(benzylmethylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol: 1H NMR (500 MHz,
CDCl3) d  7.45–7.22 (m, 10H, C6H5), 4.24 (dq, J  = 2.4, 6.4 Hz, 1H, CHCH3),  4.14 (d, J  = 11.2
Hz, 1H, NCHC6H5), 3.61 (dd, J  = 2.4, 11.8 Hz, 1H, C2OH), 3.48 (m, 2H, NCH2 6H5), 3.37
(dd, J  = 3.9, 11.7 Hz, 1H, C2OH), 2.20-2.13 (m, 1H, CCH2OH), 2.12 (s, 3H, NCH3), 1.38 (d,
J  = 6.4 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3) d  138.1, 133.5, 130.1, 129.3, 128.9, 128.5,
128.1, 127.7, 70.3, 69.9, 61.7, 60.0, 45.9, 37.0, 21.9; [a ]D = – 0.3 ° (c = 1.0, CHCl3).
A solution of (3R,4S,5R)-2,5-dimethyl-4-formyl-3-phenylisoxazolidine (Table 3, entry 3),
(51.0 mg, 0.25 mmol) was reduced to the corresponding primary alcohol (general procedure C)
and purified by silica gel chromatography (3:7 EtOAc/hexane).  The resulting oil was dissolved
in EtOH (5.0 mL) and heated to reflux.  Sodium metal (180 mg, 7.83 mmol) was added in 25 mg
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portions to the solution.  Upon formation of a white solid (4 h), the reaction was cooled to room
temperature and added to H2O (5 mL).  The resulting mixture was diluted with EtOAc (10 mL),
washed with NH4Cl (5 mL), and then extracted with EtOAc (3 x 10 mL).  The organic extracts
were combined, dried (Na2SO4), and concentrated.  Purification of the resulting oil by silica gel
chromatography (1:9 Et3N/ OAc) afforded a white solid.  The solid (9.1 mg, 0.047 mmol) was
dissolved in CH3CN (1.0 mL).  To the stirring solution was added benzyl bromide (5.8 m L, 0.048
mmol) and K2CO3 (12.0 mg, 0.086 mmol).  The reaction was heated to reflux for 14 h.  The
solution was then filtered and concentrated.  The resulting residue was purified by silica gel
chromatography (1.9:1 EtOAc/hexane) to afford a clear oil that was identical in all respects to
the compound (1R,2R,3R)-1-(benzylmethylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol (vide
supra); [a ]D = –8.4 ° (c = 1.0, CHCl3).
Determination of the absolute configuration of (3R,4S,5R)-2-benzyl-4-formyl-5-
methyl-3-(4-chlorophenyl) isoxazolidine (Table 3, entry 4) by correlation with (1R,2R,3R)-
1-(benzylamino)-2-(hydroxymethyl)-1-phenyl-butan-3-ol.
Following general procedure C, a solution of (3R,4S,5R)-2-benzyl-4-formyl-5-methyl-3-
(4-chlorophenyl) isoxazolidine (Table 3, entry 4), (25.0 mg, 0.08 mmol) was reduced to the
corresponding primary alcohol and purified by silica gel chromatography (3:7 EtOAc/hexane).
The resulting oil was dissolved in EtOH (1.2 mL) and heated to reflux.  Sodium metal (180 mg,
7.82 mmol) was added in 25 mg portions to the solution.  Upon formation of a white solid (2 h),
the reaction was cooled to room temperature and added to H2O (5 mL). The resulting mixture
was diluted with EtOAc (10 mL), washed with NH4Cl (5 mL), and then extracted with EtOAc (3
x 10 mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.  Purification
of the resulting oil by silica gel chromatography (1:39 Et3N/EtOAc) afforded a white solid that
was identical in all respects to the compound (1R,2R,3R)-1-(benzylamino)-2-(hydroxymethyl)-1-
phenyl-butan-3-ol (vide supra); [a ]D = +35.5 ° (c = 1.0, CHCl3).
Determination of the absolute configuration of (3R,4S)-2-benzyl-4-formyl-3-
phenylisoxazolidine (Table 3, entry 11) by correlation with (S)-3-benzylamino-3-phenyl-
propan-1-ol.  To Wilkinson's catalyst (72.2 mg, 0.078 mmol) was added a solution of (3R,4S)-2-
benzyl-4-formyl-3-phenylisoxazolidine (Table 3, entry 11) (20.4 mg, 0.078 mmol) in degassed
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benzene (3.5 mL).  The stirring solution was heated to reflux under a nitrogen atmosphere.  After
20 h, the reaction was cooled to room temperature and H2O (10 mL) was added.  The mixture
was extracted with Et2O (3 x 15 mL), dried (Na2SO4), and concentrated to give a red oil which
was purified by silica gel chromatography (1:9 EtOAc/hexane).  The resulting residue was
dissolved in EtOH (2 mL) and heated to reflux.  Sodium metal (120 mg, 5.22 mmol) was added
in 25 mg portions to the solution.  Upon formation of a white solid (4 h), the reaction was cooled
to room temperature and added to H2O (5 mL).  The resulting mixture was diluted with EtOAc
(10 mL), washed with NH4Cl (5 mL), and then extracted with EtOAc (3 x 10 mL).  The organic
extracts were combined, dried (Na2SO4), nd concentrated.  Purification of the resulting residue
by silica gel chromatography (EtOAc) afforded an oil that was identical in all respects to the
compound  (S)-3-benzylamino-3-phenyl-propan-1-ol;5  [a ]D (literature) = –24.7 ° (c = 0.93,
MeOH); [a ]D (found) = +20.8 ° (c = 0.93,  MeOH).
Determination of the relative configuration of (3R,4S)-2-benzyl-4-formyl-3-
napthylisoxazolidine (Table 3, entry 14) by X-ray crystallography.  To a solution of 2-
Benzyl-4-formyl-3-napthylisoxazolidine (54 mg, 0.18 mmol)tert-butanol (3.9 mL) was added 2-
methyl-2-butene (1 mL, 90 mmol), followed by dropwise of a solution of NaClO2 (152 mg, 1.69
mmol) and NaH2PO4 (178 mg, 1.29 mmol) in H2O (1.7 mL).  The biphasic solution was stirred
for 12h.  The reaction was then concentrated, diluted with H2O (10 mL) and EtOAc (10 mL), and
extracted with EtOAc (2 x 10 mL).  The combined organic extracts were washed with cold H2O,
dried (Na2SO4),  and concentrated.  Purification of the resulting residue by silica gel
chromatography (2:3 EtOAc/hexane) afforded a yellow oil which was subsequently taken up in
methanol (0.5 mL) and cooled to 0 °C.  To the reaction mixture was added 53 µL of a 1.7N
solution of KOH in methanol.  After stirring for 3 hours, the solution was concentrated and the
resulting yellow solid was recrystallized from ethanol/THF to afford crystals suitable for single
crystal X-ray diffration.
                                                
5 Shimizu, M.; Maruyama, S.; Suzuki, Y.; Fujisawa, T.  Heterocycles  1997, 45, 1883.










